Developing Silibinin Schiff base derivatives and determining their pharmacological properties, efficacy, and safety for treating CCl4-induced acute liver injury
05.05.2022 - Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous Mainz Biomed Provides Product Development Update on PancAlert 05.05.2022 / 09:01 The issuer is solely responsible for the content of this announcement. - Novel Screening Test for Pancreatic . Seite 1
Following positive domestic pilot study results for its flagship bloodstream infection (BSI) test, Australian company Microbio has appointed US clinical research consultants the Landrich Group to manage clinical evaluation trials across four sites in the USA, India, South America and Australia, with plans to submit the data generated to secure marketing clearance in Europe, India, USA and Australia. Click to read more.